Drug
Flotufolastat F 18 clinical trials
Also written Posluma and flotufolastat F18.
- studies test it
- 17
- open now
- 9
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the flotufolastat F 18 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Other names
Studies by the year they started
17 studies that test it; most in 2025 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 8 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 4
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 10
Blue Earth Diagnostics (4) · Sinotau Pharmaceutical Group (2) · NYU Langone Health (1) · M.D. Anderson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Emory University (1) · Northwestern University (1) · University of Florida (1)
Often tested with
Tested in the same studies.
Piflufolastat (1) · Lutetium-177 (1) · Gallium 68 PSMA-11 (1)
Studies
Open first, then newest update. How each study uses flotufolastat F 18 is read from its arms, and is right about nine times in ten.
Testing it · 17
- An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.RecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07185165Written as Fluorine F 18 Flotufolastat
- An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion TechniqueRecruitingPhase 2Emory UniversityNCT06865768Written as Flotufolastat F-18 Gallium
- An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN TrialRecruitingEarly Phase 1Northwestern UniversityNCT06813898Written as Flotufolastat F-18 Gallium
- POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 LesionsRecruitingPhase 2University of FloridaNCT07220720Written as Flotufolastat F 18
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland TreatmentRecruitingNot applicableHackensack Meridian HealthNCT07011342Written as 18F-rhPSMA-7.3
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active SurveillanceRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT07285057Written as Flotufolastat F18
- A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese AdultsRecruitingPhase 1Sinotau Pharmaceutical GroupNCT07149831Written as Flotufolastat F-18 Injection
- Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate CancerRecruitingNot applicableSinotau Pharmaceutical GroupNCT07115277Written as Flotufolastat F-18 Injection
- Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical ManagementRecruitingPhase 3MidLantic UrologyNCT05799248Written as rhPSMA-7.3 (18F)
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical ProstatectomyCompletedPhase 4Blue Earth DiagnosticsNCT06604442Written as flotufolastat (18F)
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical ProstatectomyActive, not recruitingPhase 3NYU Langone HealthNCT05678322Written as 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
- Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerCompletedPhase 1Blue Earth DiagnosticsNCT03995888Written as rhPSMA-7.3 (18F) Injection
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnPhase 1/2Novartis PharmaceuticalsNCT06881823Written as Flotufolastat F 18
- Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceCompletedPhase 3Blue Earth DiagnosticsNCT04186845Written as rhPSMA-7.3 (18F) Injection
- Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.CompletedPhase 3Blue Earth DiagnosticsNCT04186819Written as rhPSMA-7.3 (18F) Injection
- An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04978675Written as Fluorine F 18 rhPSMA-7.3
- 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot StudyWithdrawnEarly Phase 1University of Alabama at BirminghamNCT05707182Written as 18F-rhPSMA-7.3
Codes
What other systems call flotufolastat F 18 · ClinicalTrials.gg INT002169
- MeSH (NLM) C000731939flotufolastat F 18One source NLM
- UNII (FDA) 811W19E3OLFLOTUFOLASTAT F-18Confirmed FDA, NLM, Wikidata
- Wikidata Q120497866flotufolastat F-18Confirmed FDA, NLM, Wikidata
- Wikidata Q120693652flotufolastatConfirmed FDA, NLM, Wikidata
- DrugBank DB17851One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731939 | flotufolastat F 18 | One source NLM |
| UNII (FDA) | 811W19E3OL | FLOTUFOLASTAT F-18 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120497866 | flotufolastat F-18 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120693652 | flotufolastat | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB17851 | — | One source Wikidata |
Also registered as flotufolastat f-18 gallium (UNII XD423NK2WO).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.